Cammarata E, Airoldi C, Colombo J, et al. Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits. Dermatol Pract Concept. 2025;15(3):5845. doi:10.5826/dpc.1503a5845